Rapid Skin Improvement Seen after Treating Systemic Sclerosis Patients with Fresolimumab
June 26, 2015
(Boston)— A major treatment breakthrough for total body scarring of the skin that occurs in patients with systemic sclerosis (SSc), also known as scleroderma, may soon be available for the estimated 300,000 Americans who suffer with this condition. Currently, no treatment is available.
Boston University School of Medicine (BUSM) researchers worked with two groups of SSc patients who were treated with either one or two doses of fresolimumab, a new, unapproved drug therapy that targets a chemical mediator in the body known as TGF-beta. After seven weeks of treatment, the researchers examined the effect on skin scarring and on expression of molecular markers in the skin. In both clinical and molecular evaluations these patients showed profound decreases in skin scarring.
The researchers found that TGF-beta plays a critical role in skin scarring in patients with SSc. Although TGF-beta has been long implicated in causing scarring, this is the first clinical study to clearly show its impact on humans. The study appears online in the Journal of Clinical Investigation.
SSc is a chronic connective tissue disease generally classified as one of the autoimmune rheumatic diseases. The disease may affect the connective tissue in many parts of the body including the skin, esophagus, gastrointestinal tract (stomach and bowels), lungs, kidneys, heart and other internal organs. It also can affect blood vessels, muscles and joints. The tissues of involved organs become hard and fibrous, causing them to function less efficiently.
“Our study shows that TGF-beta plays a critical role in skin scarring in patients with systemic sclerosis,” explained corresponding author Robert Lafyatis, MD, professor of medicine at BUSM and Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases Scleroderma Center of Research Translation. “Our results indicate that blocking TGF-beta in these patients will strongly block skin scarring.”
According to the researchers scarring is the last stage in a wide variety of diseases. Proving that TGF-beta can block scarring may provide a major treatment advance for scarring-mediated organ dysfunction common to many diseases including lung fibrosis in idiopathic or radiation induced pulmonary fibrosis, liver fibrosis from viral or toxins, kidney fibrosis from diabetes and other less common kidney diseases, heart fibrosis that occurs after heart attacks and during heart failure.
A larger study with a placebo-treated group of patients is needed to confirm these results.
The National Institutes of Health reviewed and funded the grant supporting the study, but otherwise played no direct role in the study conduct. Genzyme (now a fully owned subsidiary of Sanofi) supplied the study drug and assisted with regulatory aspects, supplying the IND cross--‐reference letter and reviewing adverse events, but provided no other financial support for the study.
- Patients & Newly Diagnosed
- Healthcare Professionals